Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.42 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.33 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.32 |
| ▸ | METAP1 | P53582 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 1/20 | 0.31 |
| ▸ | STK17B | O94768 | 1/20 | 0.31 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2866010 | 0.83 | CSNK1E (0.39) | CSNK1EPOLBKMT2A | |
| SCHEMBL2868526 | 0.72 | HTR6 (0.44) | BRD4LCKGSK3BDYRK1AMAPK14 | |
| SCHEMBL2865146 | 0.71 | CSNK1E (0.41) | CSNK1EKMT2A | |
| SCHEMBL1179959 | 0.69 | CYP17A1 (0.48) | ATRCYP17A1BRD4MAPKAPK2MAPK14 | |
| SCHEMBL2866076 | 0.68 | ALDH1A1 (0.43) | POLBKMT2A | |
| SCHEMBL29435513 | 0.66 | ATR (0.56) | ATRCYP17A1MAPKAPK2METAP1POLB | |
| SCHEMBL29439709 | 0.66 | ATR (0.56) | ATRMETAP1POLBKMT2A | |
| SCHEMBL1699207 | 0.66 | ATR (0.56) | ATRMETAP1POLBKMT2A | |
| SCHEMBL30780288 | 0.65 | GSK3B (0.44) | ATRBRD4MAPKAPK2ADORA3ADORA2B | |
| SCHEMBL104530 | 0.64 | GSK3B (0.39) | ATRCYP17A1MAPKAPK2LCKKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772249-B2 | Imidazo[1,2-b]pyridazine compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-20090181985-A1 | IMIDAZO[1,2-b]PYRIDAZINE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20060211696-A1 | IMIDAZO[1,2-b]PYRIDAZINE COMPOUND | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-09-21 | — | — | US | disclosed |
| US-7078405-B2 | Imidazo[1,2-b]pyridazine compound | EISAI CO., LTD. (JP) | 2006-07-18 | — | — | US | disclosed |
| US-20040082781-A1 | Bicyclic nitrogenous fused-ring compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1364952-A1 | BICYCLIC NITROGENOUS FUSED-RING COMPOUND | Eisai Co., Ltd. (JP) | 2003-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211696-A1 | IMIDAZO[1,2-b]PYRIDAZINE COMPOUND | CRHR1, CRHR2, CRH | ATR 3467/4885CYP17A1 325/4885BRD4 433/4885 |
| US-20090181985-A1 | IMIDAZO[1,2-b]PYRIDAZINE COMPOUND | CRHR1, CRHR2, CRH | ATR 3467/4885CYP17A1 325/4885BRD4 433/4885 |
| US-20040082781-A1 | Bicyclic nitrogenous fused-ring compound | CRHR1, CRH, CRHR2 | ATR 3779/4885CYP17A1 333/4885BRD4 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.